Becton, Dickinson and Company
BDXBusiness Model
ticker: BDX step: 01 generated: 2026-05-12 source: quick-research
Becton, Dickinson and Company (BDX) — Business Overview
Business Description
BD is one of the world's largest medical technology companies, with a 125+ year history producing medical devices, instrument systems, and reagents used by healthcare professionals, researchers, and patients globally. Post-Waters spinoff (February 2026 separation of Biosciences + Diagnostic Solutions), BDX is now a pure-play medical device company focused on injection systems, infusion, surgical, and critical care monitoring. CEO Tom Polen executed "BD 2025" simplification strategy.
Revenue Model
~$21.8B FY2025 revenue (post-spin: ~$19.2B FY26E) across five segments after 2025 reorganization: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences (spun off Feb 2026 as "Waters"). Recurring sales of consumables (syringes, needles, IV catheters) + capital equipment (Alaris pumps, surgical instruments) + monitoring devices. Recurring consumables drive defensive revenue.
Products & Services
- Medical Essentials — Syringes, needles, IV catheters (BD core franchise, 30%+ revenue)
- Connected Care — Alaris infusion platform + Advanced Patient Monitoring (Edwards Critical Care acquired Sept 2024, $4.2B)
- BioPharma Systems — Prefilled syringes + pen-injectors for GLP-1 (Ozempic, Mounjaro, Wegovy) + biologics
- Interventional — Vascular access, urology (PureWick), peripheral intervention
- Life Sciences — Biosciences + Diagnostic Solutions (spun off as Waters Feb 2026)
- PureWick — External catheter for incontinence (high-margin growing franchise)
Customer Base & Go-to-Market
Hospitals (large IDNs like HCA, Tenet), physician offices, surgical centers, pharma + biotech companies (BioPharma Systems), research labs. ~70% North America, ~20% Europe, ~10% Asia. BioPharma Systems serves Eli Lilly, Novo Nordisk, Sanofi (GLP-1 + insulin manufacturers).
Competitive Position
Top 5 global medical device company. Competes with Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, Baxter. #1 globally in syringes + needles. BioPharma Systems segment unique exposure to GLP-1 supply chain. Connected Care (Alaris + APM) reinvigorated post-Critical Care acquisition.
Key Facts
- Founded: 1897
- Headquarters: Franklin Lakes, NJ
- Employees: ~75,000 (pre-spin)
- Exchange: NYSE (BDX)
- Sector / Industry: Healthcare / Medical Devices
- Market Cap: ~$60B (post-spin)
- CEO: Tom Polen (since 2020; chairman + president + CEO)
Recent Catalysts
ticker: BDX step: 12 generated: 2026-05-12 source: quick-research
Becton, Dickinson and Company (BDX) — Investment Catalysts & Risks
Bull Case Drivers
GLP-1 prefilled syringe + pen-injector supply chain monopoly — BD is the primary supplier of glass prefilled syringes and pen-injectors used for popular GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound). BioPharma Systems segment scaling manufacturing capacity to meet unprecedented global demand. GLP-1 TAM growing $50B+ → $100B+ by 2030. BD has 30+ year relationships with Lilly, Novo Nordisk. Multi-year supply contracts.
Waters spinoff (Feb 2026) = pure-play med device focus — Spun off Life Sciences (Biosciences + Diagnostic Solutions) as "Waters" in February 2026. New BD is now pure-play medical device company with higher margin profile + simpler narrative. $2B buyback authorization to offset spin EPS dilution. Sum-of-parts unlock thesis.
Edwards Critical Care (APM) integration accretive 2026 — $4.2B acquisition of Edwards' Critical Care unit (Sept 2024) added AI-driven hemodynamic monitoring + Swan-Ganz catheters. Connected Care segment leverages BD's sales channel into critical care ICU. Synergies + cross-sell accelerating in 2026. Strategic fit complements Alaris infusion platform.
53-year dividend track record + BD Excellence + 25% op margin — 53 consecutive years of dividend increases (Dividend Aristocrat). FY25 adj op margin record 25% (+80bps YoY) driven by BD Excellence operating system. Continued margin expansion target 100bps annually. FCF $3B+ supports dividend + $2B buyback + portfolio investment.
Bear Case Risks
FY2026 revenue declines 12% YoY = $19.2B post-spin — FY26 reported revenue falls ~12% to $19.2B reflecting Life Sciences removal. Adj EPS $12.35-12.65 implies ~6% growth at midpoint — bears worry New BD growth is structurally low-single-digit. Sub-10% potential forward returns + less than 4% earnings growth warrant continued Hold stance per Morningstar.
Edwards Critical Care integration complexity + leverage — $4.2B acquisition added $4B+ debt. Net debt/EBITDA ~2.6x. Integration of Edwards Critical Care business into BD culture + sales channel is complex. If APM synergies underdeliver, the bull case slips. Tariff impact 200bps to FY25 EPS — ongoing pressure.
Tom Polen execution + portfolio remains complex — BD 2025 simplification narrative completed with spin, but New BD still has 5 segments + diversified portfolio. Critics argue further portfolio simplification needed. Tom Polen tenure shows mixed execution: Alaris recall historical issue, slow recovery in some growth segments.
Hospital capex + supply chain headwinds — Hospital capital equipment budgets pressured by labor cost inflation + reimbursement cuts. Connected Care segment (Alaris, APM) sensitive to hospital capex cycle. If economic slowdown extends, capital equipment orders defer. Tariff/supply chain inflation also persistent margin pressure.
Upcoming Events
- Q2 FY26 earnings (May 2026) — First quarter post Waters spin
- Q3 FY26 earnings (August 2026) — Mid-year guide + GLP-1 ramp visibility
- Q4 FY26 earnings (November 2026) — Full-year report + FY27 setup
- GLP-1 capacity expansion announcements — Direct BioPharma Systems demand
- Buyback execution + capital allocation — $2B authorization to deploy
Analyst Sentiment
Sell-side consensus is Moderate Buy / Hold with average price targets in the $215-250 range vs. recent ~$200 trading levels (~7-25% upside). Bulls cite GLP-1 supply moat + Waters spinoff + APM integration + 53-yr dividend + buyback. Bears focus on revenue decline post-spin + low organic growth + leverage + tariff. BDX is widely viewed as a defensive med device franchise with structural GLP-1 exposure + valuation-dependent upside.
Research Date
Generated: 2026-05-12
Moat Analysis
WideBDX holds five of seven Helmer Powers, with switching costs (Alaris platform) and a cornered GLP-1 syringe resource as the dominant moat sources.
Bull Case
Alaris post-clearance pent-up demand recovery, accelerating GLP-1 syringe growth, and D&A amortization burn-off could drive meaningful multiple re-rating for BDX.
Bear Case
Elevated leverage, Edwards Critical Care integration risk, and faster-than-expected oral GLP-1 adoption could compress earnings and unwind BDX's valuation premium.
Top Institutional Holders
- Vanguard Group11.5% · 31.6M sh
- BlackRock8.5% · 23.4M sh
- State Street5.1% · 14M sh
Full Investment Thesis
The full research tier ($2.00) adds 7 dimensions that constitute the investment thesis proper.